Epilepsy Seizure Articles & Analysis
15 news found
The jointly developed therapy features a micro-infusion device that tightly controls drug delivery to a region of the brain for patients with medically refractory epilepsy. ADDRESS is the first multi-center dose ranging clinical study assessing intracerebroventricular (ICV) delivery of the drug valproate (valproate sodium) in patients with focal seizures, with ...
“About a third of individuals with epilepsy have drug-resistant seizures. Removal or ablation of the affected temporal lobe can be an option, but many people with epilepsy are not eligible or interested in a tissue-destructive procedure. ...
These algorithms can be focused on therapeutic areas such as neurodegenerative disorders, epilepsy, sleep disorders and mental illness. For example, Beacon is currently assessing novel EEG signatures in Alzheimer's disease patients to identify which patients may or may not benefit from a specific type of therapy. ...
“We are excited to have begun recruiting for the clinical trial and to evaluate the safety and efficacy of NRTX-1001, which has the potential to improve quality of life for people living with drug-resistant focal epilepsy. The data, generated from a single targeted administration in a preclinical model of chronic mesial temporal lobe epilepsy, demonstrate ...
NeuroSigma, Inc., a bioelectronic medical device company, today announced FDA Breakthrough Device Designation for its Monarch eTNS System® for “adjunctive use for reducing the frequency of seizures in individuals 18 years of age or older diagnosed with epilepsy characterized by partial-onset seizures, with or without secondary ...
Prior to working in the pharmaceutical industry, he was in clinical practice as a neurologist at the Barrow Neurological Institute in Arizona for 10 years, where he was director of the epilepsy program. He has authored or co-authored over 50 full-length papers in neurology-related areas. ...
“These preclinical data, in a model of drug-resistant epilepsy, demonstrate that a single administration of NRTX-1001 achieves durable and significant suppression of seizures and reduction of hippocampal pathology, important metrics for the potential resolution of chronic focal-onset epilepsy. ...
The company’s beachhead product, available in Europe, Australia and New Zealand, is for people with absence epilepsy, the most common pediatric epilepsy syndrome causing absence seizures, which mostly look like daydreaming. Yet for the person themselves an absence seizure is a full blackout with no recollection of what ...
For the August installment of the Healthtech Leader of the Month series, we interviewed Aswin Gunasekar, founder and CEO of Zeto. Zeto is a device-driven platform for acquiring, accessing, and interpreting electroencephalograms (EEGs). An EEG is a test used to evaluate electrical activity in the ...
The prevalence of sleep disorders, epilepsy and cardiovascular disease pose a significant challenge to the US healthcare system. Notably, 70 million Americans suffer from some form of a sleep disorder, 1 in 26 people will develop epilepsy or recurrent seizures during their lifetime, and 48% of all adults in the US have some type of cardiovascular ...
In comparison to standard CBD, CQ-001 (cannabidiol "CBD" + IP formula - essential fatty acids) demonstrated 40% more seizure reduction at a medium dose in the maximal electroshock seizure (MES) model. ...
Belgian health tech startup epihunter NV is awarded a $200,000 grant from Epilepsy Foundation to further validate and market their CE labelled epileptic seizure detection algorithm. ...
“Including video in epileptic seizure detection has the potential to change the way neurologists and epileptologists assess and document seizure frequency and the effect of therapy,” says Dr Sándor Beniczky, Head of Clinical Neurophysiology at the Danish Epilepsy Centre. It is estimated that 1 in 100 people have ...
Belgian startup, epihunter, introduces automated video functionality to their CE-marked seizure detection app - a breakthrough for children and adults with epilepsy, their families and doctors. ...
Zeto’s CEO Aswin Gunasekar was in business school at the University of Texas, Austin, when he took an interest in epilepsy diagnosis after watching a family member battle the condition. ...